1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-morpholinophenyl)urea | 714962-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-morpholinophenyl)urea
• 英文别名: 1-(4-Chloro-3-trifluoromethyl-phenyl)-3-(4-morpholin-4-yl-phenyl)-urea；1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(4-morpholin-4-ylphenyl)urea
• CAS: 714962-02-4
• 化学式: C₁₈H₁₇ClF₃N₃O₂
• 分子量: 399.8
• InChiKey: RBBMHGSLMFKYBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] SORAFENIB ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES DE SORAFENIB ET LEURS UTILISATIONS
  申请人：UNIV COLUMBIA

  公开号：WO2015051149A1

  公开（公告）日：2015-04-09

  The present invention provides, inter alia, compounds according to formula I. Also provided are pharmaceutical compositions and kits containing such compounds. Methods for using such compounds, compositions, and kits for treating a subject having system xc-, dysregulation for activating ferroptosis, for inhibiting system xc- in a cell, and for monitoring treatment of a subject having system xc- dysregulation are provided as well.

  本发明提供了根据式I的化合物，还提供了含有这种化合物的药物组合物和试剂盒。还提供了使用这种化合物、组合物和试剂盒治疗具有系统xc-失调以激活铁死亡、在细胞中抑制系统xc-以及监测具有系统xc-失调的受试者治疗的方法。
• Differential tumor cytotoxicity compounds and compositions
  申请人：IRM LLC, a Delaware Limited Liability Company

  公开号：US20040132786A1

  公开（公告）日：2004-07-08

  The invention is directed to novel biaryl derivatives, to the uses of these compounds in various medicinal applications, including the treatment, prevention and control of proliferative diseases such as tumors, and to pharmaceutical compositions comprising these compounds. Compounds of the invention can be used to treat or prevent diseases or disorders that involve the activity of MIF-1 and/or adenosine kinase.

  该发明涉及新型联苯衍生物，以及这些化合物在各种医学应用中的用途，包括治疗、预防和控制增殖性疾病，如肿瘤，以及包含这些化合物的药物组合物。该发明的化合物可用于治疗或预防涉及MIF-1和/或腺苷激酶活性的疾病或疾病。
• METHODS OF CANCER TREATMENT
  申请人：Ferro Therapeutics, Inc.

  公开号：US20200138829A1

  公开（公告）日：2020-05-07

  The present disclosure relates to a method of treating a subject with cancer with a ferroptosis inducer, including use of the ferroptosis inducer in combination with a second therapeutic agent.
• US7125997B2
  申请人：——

  公开号：US7125997B2

  公开（公告）日：2006-10-24